Abiopharma

New Form 6-K - ASTRAZENECA PLC Filed: 2025-07-29 AccNo: 0001104659-25-071432 Size: 12 MB

Hoth Therapeutics Notification (HOTH)

New Form 4 - CEL SCI CORP Filed: 2025-07-29 AccNo: 0001236030-25-000008 Size: 4 KB

New Form SC14D9C - DURECT CORP Filed: 2025-07-29 AccNo: 0001193125-25-167178 Size: 16 KB

Simulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor® Models with Enhanced AI Drug Design

New Form 6-K - China SXT Pharmaceuticals, Inc. Filed: 2025-07-29 AccNo: 0001213900-25-068429 Size: 345 KB

New Form 6-K - KONINKLIJKE PHILIPS NV Filed: 2025-07-29 AccNo: 0000313216-25-000029 Size: 3 MB

Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer

New Form 8-K - DURECT CORP Filed: 2025-07-29 AccNo: 0001193125-25-167173 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements …

Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy

New Form 8-K - REPLIGEN CORP Filed: 2025-07-29 AccNo: 0000950170-25-099389 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - Kiniksa Pharmaceuticals International, plc Filed: 2025-07-29 AccNo: 0001104659-25-071413 Size: 275 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

SIGA - SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results